APhA and other organizations call for consistent naming of biosimilars

APhA and 18 other health care organizations urged FDA to forgo allowing different names for biosimilars and biologics. Allowing for different names would lead to safety issues and confuse health care providers, the group said in a June 30 letter to Stephen Ostroff, MD, FDA's acting commissioner.

APhA and 18 other health care organizations urged FDA to forgo allowing different names for biosimilars and biologics. Allowing for different names would lead to safety issues and confuse health care providers, the group said in a June 30 letter to Stephen Ostroff, MD, FDA's acting commissioner. FDA's position regarding how so-called reference biologics, biosimilars and interchangeable biologics should be named is unclear at this time. "Requiring different [international nonproprietary names] for biologics and biosimilars could lead to patient and prescriber confusion, increasing the possibility of medication errors, and would also effectively separate the biosimilar from existing safety information about the underlying molecule," the organizations stated.

Ad Position
Bottom Center Aligned